Today: 9 June 2026
IREN stock price slides after hours as Q2 loss hits and Microsoft GPU financing takes focus
6 February 2026
2 mins read

IREN stock price slides after hours as Q2 loss hits and Microsoft GPU financing takes focus

New York, February 5, 2026, 18:49 EST — After-hours

Shares of IREN Limited dropped roughly 11% in late after-hours trading Thursday, settling at $39.79 after fluctuating between $44.91 and $28.70 during the session. Around 69.9 million shares changed hands, per market data.

Crypto-linked stocks took a sharp hit following bitcoin’s roughly 14% drop to near $63,367. Marathon Digital slid about 19%, Riot Platforms dropped around 15%, and CleanSpark lost roughly 19%.

For IREN, the decline comes at a tricky time. The company remains tied to bitcoin mining economics, yet the stock is now more focused on its ability to quickly develop and fund a sizable AI cloud business that could shift the narrative.

IREN reported cash and cash equivalents of $2.8 billion as of Jan. 31. Quarterly revenue dropped to $184.7 million from $240.3 million in the previous quarter, driven by bitcoin mining revenue falling to $167.4 million, while AI cloud services revenue increased to $17.3 million. Net income swung to a $155.4 million loss. Adjusted EBITDA, which excludes certain items, slipped to $75.3 million, weighed down by substantial non-cash charges: $219.2 million linked to convertible-note hedges and induced conversions, $31.8 million in mining hardware impairments as the company replaces ASICs—bitcoin-mining chips—with GPUs, and $58.2 million in stock-based compensation. IREN also highlighted $3.6 billion in GPU financing for its Microsoft contract at an interest rate below 6%, alongside a $1.9 billion prepayment. The company announced plans for a 1.6-gigawatt data-center campus in Oklahoma and kept its end-2026 targets steady at 140,000 GPUs and $3.4 billion in annual recurring revenue (ARR).

During the earnings call, co-CEO Daniel Roberts assured analysts that “Power is not a constraint for us,” highlighting strong demand for both new and older GPU models. Chief commercial officer Kent Draper pointed out that “time to data center” now plays a crucial role in commercial discussions. Meanwhile, IREN detailed a delayed-draw term loan arranged by Goldman Sachs and J.P. Morgan. Investing.com

In its quarterly filing, IREN revealed a deal with Microsoft inked in November 2025 to deliver dedicated GPU services at its Childress, Texas facility. The contract is pegged at roughly $9.7 billion over around five years. The company noted it usually sells all bitcoin mined daily and had no bitcoin holdings on its balance sheet as of Dec. 31. Installed hashrate capacity was about 46 exahashes per second.

A separate Form 8-K filed Thursday noted the company furnished the earnings release as an exhibit instead of “filing” it, which limits liability under Section 18 of the Exchange Act. SEC

Some details remain unsettled. IREN noted that GPU financing and interest rates hinge on pricing parameters, base rates, and final documentation. It also warned its $3.4 billion ARR target isn’t fully locked in, relying on timely delivery and commissioning of GPUs.

The key wild card is still execution: turning power and data-center capacity into signed deals, then rushing GPUs to site and getting them powered up fast enough to start generating revenue. Any delays could hand control back to the crypto side of the business.

Traders will keep an eye on bitcoin as well. A sharper drop could hit miner stocks hard, no matter the individual company news. On the flip side, a rebound might hide poor quarter-to-quarter results.

When Nasdaq trading kicks back in on Friday, February 6, IREN’s shares should offer a clearer picture. Investors will be watching closely for updates on financing terms and how fast the AI rollout is progressing.

Stock Market Today

  • Semiconductor Stock Poised to Surpass Micron Technology by 2028
    June 9, 2026, 10:18 AM EDT. Micron Technology has surged nearly 800% recently, driven by high demand and pricing power in memory chips, pushing its market cap past $1 trillion. However, analysts predict supply constraints easing by 2028 could cause earnings to peak and decline, potentially halving share value to around $517.50. Meanwhile, a major semiconductor competitor valued around $650 billion is expanding production, potentially surpassing Micron's value by 2028. The industry faces cyclical dynamics as new manufacturing capacity comes online globally, impacting pricing and earnings. Investors are watching these shifts closely for long-term positioning amid evolving chip supply and demand.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Exxon Mobil stock price slips after oil drops; XOM traders brace for U.S.-Iran talks
Previous Story

Exxon Mobil stock price slips after oil drops; XOM traders brace for U.S.-Iran talks

Super Micro (SMCI) stock slides 9% after earnings spike — what to watch before Friday’s trade
Next Story

Super Micro (SMCI) stock slides 9% after earnings spike — what to watch before Friday’s trade

Go toTop